Active substance
Venlafaxine
- SFDA 24
- US FDA 51
- Health Canada 36
- US price lines 15
- NHS prices 13
- Safety 16
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Binoven XL | 150 mg | Prolonged-release capsule · Oral use | 30 Blister | SAR 173.10 | Generic · Prescription | ALTAIF PHARMACEUTICALS COMPANY | Valid |
| Binoven XL | 75 mg | Prolonged-release capsule · Oral use | 30 Blister | SAR 102.70 | Generic · Prescription | ALTAIF PHARMACEUTICALS COMPANY | Valid |
| EFEXOR XR 150 MG CAPSULES | 150 mg | Prolonged-release capsule · Oral use | 14 Blister | SAR 95.05 | NCE · Prescription | Viatris Arabia Limited | Valid |
| EFEXOR XR 75 MG CAPSULES | 75 mg | Prolonged-release capsule · Oral use | 14 Blister | SAR 56.40 | NCE · Prescription | Viatris Arabia Limited | Valid |
| VENEX XR 150MG CAPSULE | 150 mg | Modified-release capsule · Oral use | 14 Blister | SAR 90.30 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| VENEX XR 75MG CAPSULE | 75 mg | Modified-release capsule · Oral use | 14 Blister | SAR 54.10 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| VEXAL XR 150 MG EXTENDED RELEASE CAPSULE | 150 mg | Modified-release capsule · Oral use | 14 Blister | SAR 95.05 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| VEXAL XR 37.5 MG EXTENDED RELEASE CAPSULE | 37.5 mg | Modified-release capsule · Oral use | 14 Blister | SAR 30.05 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| VEXAL XR 75 MG EXTENDED RELEASE CAPSULE | 75 mg | Modified-release capsule · Oral use | 14 Blister | SAR 60.10 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| VelExel | 150 mg | Prolonged-release tablet · Oral use | 28 Blister | SAR 121.90 | NCE · Prescription | Medical Valley Invest AB | Valid |
| VelExel | 75 mg | Prolonged-release tablet · Oral use | 28 Blister | SAR 60.95 | NCE · Prescription | Medical Valley Invest AB | Valid |
| EFEXOR 37.5MG TAB | 37.5 mg | Tablet · Oral use | 28 Blister | SAR 64.30 | NCE · Prescription | WYETH | Withdrawn by MAH · Not Marketed |
| EFEXOR 50MG TAB | 50 mg | Tablet · Oral use | 28 Blister | SAR 78.60 | NCE · Prescription | WYETH | Withdrawn by MAH · Not Marketed |
| EFEXOR 75MG TAB | 75 mg | Tablet · Oral use | 28 Blister | SAR 96.65 | NCE · Prescription | WYETH | Withdrawn by MAH · Not Marketed |
| FENIXOR 25MG TAB. | 25 mg | Tablet · Oral use | 30 Blister | SAR 21.75 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Withdrawn by MAH · Not Marketed |
| FENIXOR 37.5MG TAB. | 37.5 mg | Tablet · Oral use | 30 Blister | SAR 32.65 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Withdrawn by MAH · Not Marketed |
| FENIXOR 50MG TAB. | 50 mg | Tablet · Oral use | 30 Blister | SAR 43.50 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Withdrawn by MAH · Not Marketed |
| FENIXOR 75MG TAB. | 75 mg | Tablet · Oral use | 30 Blister | SAR 65.30 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Withdrawn by MAH · Not Marketed |
| VENAXINE | 50 mg | Tablet · Oral use | 30 Blister | SAR 58.95 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| VENAXINE | 37.5 mg | Tablet · Oral use | 30 Blister | SAR 48.20 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| VENAXINE | 75 mg | Tablet · Oral use | 30 Blister | SAR 72.50 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| VENAXINE XR 150 MG CAPSULES | 150 mg | Modified-release capsule · Oral use | 14 Blister | SAR 67.70 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| VENAXINE XR 75 MG CAPSULES | 75 mg | Modified-release capsule · Oral use | 14 Blister | SAR 33.85 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| VENEX XR 37.5 MG CAPSULE | 37.5 mg | Modified-release capsule · Oral use | 14 Blister | SAR 27.05 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE BIPOLAR I DEPRESSION; ALZHEIMER / DEMENTIA; ANXIETY DISORDERS; BIPOLAR II DISORDER; DEPRESSION; MENOPAUSE; MENSTRUAL DISORDERS; MIGRAINE/ HEADACHE; NARCOLEPSY AND CATAPLEXY; NEUROPATHIC PAIN; PAIN MANAGEMENT IN CANCER PATIENTS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| EFFEXOR XR | EQ 37.5MG BASE; EQ 75MG BASE; EQ 150MG BASE | capsule, extended release · oral | UPJOHN | Prescription | 20 Oct 1997 |
| VENLAFAXINE HYDROCHLORIDE | EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | tablet · oral | TEVA | Prescription | 3 Aug 2006 |
| VENLAFAXINE HYDROCHLORIDE | EQ 37.5MG BASE; EQ 75MG BASE; EQ 150MG BASE; EQ 225MG BASE | tablet, extended release · oral | OSMOTICA PHARM US | Prescription | 20 May 2008 |
| VENLAFAXINE HYDROCHLORIDE | EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | tablet · oral | ZYDUS PHARMS USA | Prescription | 13 Jun 2008 |
| VENLAFAXINE HYDROCHLORIDE | EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | tablet · oral | DR REDDYS LABS LTD | Prescription | 13 Jun 2008 |
| VENLAFAXINE HYDROCHLORIDE | EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | tablet · oral | SUN PHARM INDS INC | Prescription | 13 Jun 2008 |
| VENLAFAXINE HYDROCHLORIDE | EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | tablet · oral | HERITAGE | Prescription | 9 Jan 2009 |
| VENLAFAXINE HYDROCHLORIDE | EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | tablet · oral | AUROBINDO PHARMA | Prescription | 7 Apr 2010 |
| VENLAFAXINE HYDROCHLORIDE | EQ 37.5MG BASE; EQ 75MG BASE; EQ 150MG BASE | capsule, extended release · oral | TEVA | Prescription | 28 Jun 2010 |
| VENLAFAXINE HYDROCHLORIDE | EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | tablet · oral | ALEMBIC PHARMS LTD | Prescription | 14 Dec 2010 |
| VENLAFAXINE HYDROCHLORIDE | EQ 37.5MG BASE; EQ 75MG BASE; EQ 150MG BASE | capsule, extended release · oral | SCIEGEN PHARMS | Prescription | 14 Apr 2011 |
| VENLAFAXINE HYDROCHLORIDE | EQ 37.5MG BASE; EQ 75MG BASE; EQ 150MG BASE | capsule, extended release · oral | ZYDUS PHARMS USA INC | Prescription | 14 Apr 2011 |
| VENLAFAXINE HYDROCHLORIDE | EQ 37.5MG BASE; EQ 75MG BASE; EQ 150MG BASE | capsule, extended release · oral | AUROBINDO PHARMA LTD | Prescription | 14 Apr 2011 |
| VENLAFAXINE HYDROCHLORIDE | EQ 37.5MG BASE; EQ 75MG BASE; EQ 150MG BASE | capsule, extended release · oral | DR REDDYS LABS LTD | Prescription | 6 May 2011 |
| VENLAFAXINE HYDROCHLORIDE | EQ 37.5MG BASE; EQ 75MG BASE; EQ 150MG BASE | capsule, extended release · oral | ORBION PHARMS | Prescription | 11 Jul 2011 |
| VENLAFAXINE HYDROCHLORIDE | EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | tablet · oral | YAOPHARMA CO LTD | Prescription | 28 May 2015 |
| VENLAFAXINE HYDROCHLORIDE | EQ 150MG BASE; EQ 225MG BASE | tablet, extended release · oral | MPP PHARMA | Prescription | 24 Mar 2017 |
| VENLAFAXINE HYDROCHLORIDE | EQ 37.5MG BASE; EQ 75MG BASE; EQ 150MG BASE | capsule, extended release · oral | MACLEODS PHARMS | Prescription | 5 Oct 2017 |
| VENLAFAXINE HYDROCHLORIDE | EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | tablet · oral | CADILA PHARMS LTD | Prescription | 21 Nov 2018 |
| VENLAFAXINE HYDROCHLORIDE | EQ 37.5MG BASE; EQ 75MG BASE; EQ 150MG BASE | capsule, extended release · oral | PLATINUM | Prescription | 23 Nov 2018 |
| VENLAFAXINE HYDROCHLORIDE | EQ 37.5MG BASE; EQ 75MG BASE; EQ 150MG BASE | capsule, extended release · oral | ANNORA PHARMA | Prescription | 8 Jul 2019 |
| VENLAFAXINE HYDROCHLORIDE | EQ 75MG BASE; EQ 150MG BASE; EQ 225MG BASE | tablet, extended release · oral | CADILA PHARMS LTD | Prescription | 29 Aug 2019 |
| VENLAFAXINE HYDROCHLORIDE | EQ 150MG BASE; EQ 225MG BASE | tablet, extended release · oral | ADAPTIS | Prescription | 31 Oct 2019 |
| VENLAFAXINE HYDROCHLORIDE | EQ 37.5MG BASE; EQ 75MG BASE; EQ 150MG BASE; EQ 100MG BASE | capsule, extended release · oral | ADAPTIS | Prescription | 12 Mar 2020 |
| VENLAFAXINE HYDROCHLORIDE | EQ 37.5MG BASE; EQ 75MG BASE; EQ 150MG BASE; EQ 225MG BASE | tablet, extended release · oral | ASCENT PHARMS INC | Prescription | 21 Oct 2020 |
26 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ACT VENLAFAXINE XR | 02304317 | 37.5 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | TEVA CANADA LIMITED |
| ACT VENLAFAXINE XR | 02304325 | 75 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | TEVA CANADA LIMITED |
| ACT VENLAFAXINE XR | 02304333 | 150 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | TEVA CANADA LIMITED |
| AURO-VENLAFAXINE XR | 02452839 | 37.5 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | AURO PHARMA INC |
| AURO-VENLAFAXINE XR | 02452847 | 75 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | AURO PHARMA INC |
| AURO-VENLAFAXINE XR | 02452855 | 150 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | AURO PHARMA INC |
| EFFEXOR XR | 02237279 | 37.5 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | BGP PHARMA ULC |
| EFFEXOR XR | 02237280 | 75 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | BGP PHARMA ULC |
| EFFEXOR XR | 02237282 | 150 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | BGP PHARMA ULC |
| M-VENLAFAXINE XR | 02471280 | 37.5 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | MANTRA PHARMA INC |
| M-VENLAFAXINE XR | 02471299 | 75 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | MANTRA PHARMA INC |
| M-VENLAFAXINE XR | 02471302 | 150 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | MANTRA PHARMA INC |
| PMSC-VENLAFAXINE XR | 02521466 | 37.5 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | PHARMASCIENCE INC |
| PMSC-VENLAFAXINE XR | 02521474 | 150 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | PHARMASCIENCE INC |
| PMSC-VENLAFAXINE XR | 02521482 | 75 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | PHARMASCIENCE INC |
| SANDOZ VENLAFAXINE XR | 02310317 | 37.5 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ VENLAFAXINE XR | 02310325 | 75 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ VENLAFAXINE XR | 02310333 | 150 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | SANDOZ CANADA INCORPORATED |
| TARO-VENLAFAXINE XR | 02380072 | 37.5 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | SUN PHARMA CANADA INC |
| TARO-VENLAFAXINE XR | 02380080 | 75 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | SUN PHARMA CANADA INC |
| TARO-VENLAFAXINE XR | 02380099 | 150 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | SUN PHARMA CANADA INC |
| VENLAFAXINE XR | 02339242 | 37.5 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | PRO DOC LIMITEE |
| VENLAFAXINE XR | 02339250 | 75 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | PRO DOC LIMITEE |
| VENLAFAXINE XR | 02339269 | 150 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | PRO DOC LIMITEE |
| VENLAFAXINE XR | 02354713 | 37.5 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | SANIS HEALTH INC |
11 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | EFFEXOR XR 150 MG CAPSULE | $21.62193 | per EA | 23 Sep 2026 |
| US NADAC | EFFEXOR XR 37.5 MG CAPSULE | $17.70418 | per EA | 23 Sep 2026 |
| US NADAC | EFFEXOR XR 75 MG CAPSULE | $19.81997 | per EA | 23 Sep 2026 |
| US NADAC | VENLAFAXINE HCL 100 MG TABLET | $0.10992 | per EA | 23 Sep 2026 |
| US NADAC | VENLAFAXINE HCL 25 MG TABLET | $0.07226 | per EA | 23 Sep 2026 |
| US NADAC | VENLAFAXINE HCL 37.5 MG TABLET | $0.07145 | per EA | 23 Sep 2026 |
| US NADAC | VENLAFAXINE HCL 50 MG TABLET | $0.08941 | per EA | 23 Sep 2026 |
| US NADAC | VENLAFAXINE HCL 75 MG TABLET | $0.08507 | per EA | 23 Sep 2026 |
| US NADAC | VENLAFAXINE HCL ER 150 MG CAP | $0.11901 | per EA | 30 Sep 2026 |
| US NADAC | VENLAFAXINE HCL ER 150 MG TAB | $0.22771 | per EA | 23 Sep 2026 |
| US NADAC | VENLAFAXINE HCL ER 225 MG TAB | $0.47118 | per EA | 23 Sep 2026 |
| US NADAC | VENLAFAXINE HCL ER 37.5 MG CAP | $0.07912 | per EA | 30 Sep 2026 |
| NHS Drug Tariff | Venlafaxine 150mg modified-release capsules | £3.53 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Venlafaxine 150mg modified-release tablets | £8.97 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Venlafaxine 225mg modified-release capsules | £13.98 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Venlafaxine 225mg modified-release tablets | £33.60 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Venlafaxine 300mg modified-release tablets | £44.97 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Venlafaxine 37.5mg modified-release capsules | £2.84 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Venlafaxine 37.5mg modified-release tablets | £7.30 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Venlafaxine 37.5mg tablets | £4.09 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Venlafaxine 37.5mg/5ml oral solution sugar free | £199.63 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Venlafaxine 75mg modified-release capsules | £1.94 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Venlafaxine 75mg modified-release tablets | £3.17 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Venlafaxine 75mg tablets | £5.04 | 56 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- EMA PRAC 9 Jul 2026 PRAC signal: Cardiotoxicity
Action for MAH: update of the product information: No - EMA PRAC 27 Nov 2025 PRAC signal: Cardiotoxicity
Action for MAH: update of the product information: No - US FDA 18 Aug 2023 EFFEXOR XR — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Aug 2023 VENLAFAXINE BESYLATE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Aug 2023 VENLAFAXINE HYDROCHLORIDE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 29 Sep 2022 PRAC signal: Pulmonary hypertension
Action for MAH: update of the product information: No - EMA PRAC 10 Mar 2022 PRAC signal: Pulmonary hypertension
Action for MAH: update of the product information: No - EMA PRAC 1 Oct 2020 PRAC signal: Postpartum haemorrhage
Action for MAH: update of the product information: Yes - EMA PRAC 11 Jun 2020 PRAC signal: Postpartum haemorrhage
Action for MAH: update of the product information: No - EMA PRAC 12 Mar 2020 PRAC signal: Postpartum haemorrhage
Action for MAH: update of the product information: No - EMA PRAC 16 May 2019 PRAC signal: Persistent sexual dysfunction after drug withdrawal
Action for MAH: update of the product information: Yes - EMA PRAC 31 Oct 2018 PRAC signal: Persistent sexual dysfunction after drug withdrawal
Action for MAH: update of the product information: No - EMA PRAC 6 Sep 2018 PRAC signal: Persistent sexual dysfunction after drug withdrawal
Action for MAH: update of the product information: No - EMA PRAC 2 Sep 2016 PRAC signal: Risk of autism spectrum disorders (ASD) after maternal use of SSRI/SNRI
Action for MAH: update of the product information: No - EMA PRAC 13 May 2016 PRAC signal: Risk of autism spectrum disorders (ASD) after maternal use of SSRI/SNRI
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.